Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double Dose Icotinib for NSCLC Brain Metastases
NCT01688713Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2012
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01688713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688713.